Foa R, Norton L, Seidman A D
Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, Turin, Italy.
Int J Clin Lab Res. 1994;24(1):6-14. doi: 10.1007/BF02592403.
Taxol (paclitaxel), an anti-microtubule agent extracted from the needles and bark of the Pacific yew tree Taxus brevifolia, has shown a remarkable anti-neoplastic effect in human cancer in phase I studies and early phase II and III trials thus far conducted. This has been reported primarily in advanced ovarian and breast cancer, although significant activity has also been documented in small-cell and non-small-cell lung cancer, head and neck cancers, and with lower activity in metastatic melanoma. The clinical utilization of Taxol had been previously somewhat restricted by its limited availability, a limitation that has recently been overcome by combined efforts of pharmaceutical, agricultural, and governmental agencies. In this review we shall address the pre-clinical data which have led to the use of Taxol in man, the main clinical results thus far obtained, the toxicities associated with its use, current ongoing trials and future clinical directions of this promising agent.
紫杉醇是从太平洋紫杉（短叶红豆杉）的针叶和树皮中提取的一种抗微管药物。在目前进行的I期研究以及早期II期和III期试验中，它已在人类癌症中显示出显著的抗肿瘤作用。到目前为止，这主要在晚期卵巢癌和乳腺癌中得到报道，不过在小细胞和非小细胞肺癌、头颈癌中也记录到了显著活性，而在转移性黑色素瘤中的活性较低。紫杉醇的临床应用此前曾因供应有限而受到一定限制，不过制药、农业和政府机构的共同努力最近克服了这一限制。在这篇综述中，我们将阐述促使紫杉醇用于人体的临床前数据、迄今取得的主要临床结果、与其使用相关的毒性、当前正在进行的试验以及这种有前景的药物未来的临床应用方向。
